Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

How to Transition From Pediatric to Adult NF1 Care

At a Glance

Transitioning from pediatric to adult NF1 care should begin between ages 12 and 14. A successful transition requires gradually building the teenager's independence, assembling a multidisciplinary team of adult specialists, and ensuring detailed medical records and tumor baselines are transferred.

Transitioning a teenager from a pediatric Neurofibromatosis type 1 (NF1) clinic to adult care is a multi-year process that requires deliberate, structured planning. Because NF1 is a complex, lifelong condition, simply handing a young adult a list of new doctors is not enough. A successful transition involves starting early, gradually shifting responsibility to the teenager, building a new multidisciplinary team of adult specialists, and ensuring all medical records and tumor baselines are securely transferred.

The Importance of Structured Transition Planning

Transition planning should ideally begin early in adolescence, often between the ages of 12 and 14 [1][2]. Starting early gives your teenager years to practice managing their health while still under the guidance of a parent or guardian. Experts recommend using a structured framework, such as the “Six Core Elements of Health Care Transition,” which outlines a clear path from pediatric to adult care through ongoing tracking, readiness assessments, and formal transfer of care [3][4].

When the transition is poorly managed, young adults with NF1 can experience gaps in care, which can negatively impact their education, career, relationships, and overall quality of life [5]. Having a timeline can help demystify the process:

  • Ages 12-14: Learning the basics about NF1 and their own medical history.
  • Ages 15-17: Practicing independence during appointments and learning to navigate the healthcare system.
  • Age 18+: Formal transfer of care to adult providers.

Assessing and Building Transition Readiness

To figure out what skills your teenager needs to work on, clinics often use transition readiness tools like the Transition Readiness Assessment Questionnaire (TRAQ). The TRAQ measures a patient’s ability to handle health-related tasks, such as filling prescriptions, calling to make appointments, and understanding health insurance.

Research shows that adolescents and young adults with NF1 often express confidence in some areas of transition readiness, but they typically score lower than their healthy peers on these assessments—particularly in tasks like handling insurance and managing medical emergencies [5][6].

Many teenagers with NF1 have learning disabilities or executive functioning delays, which can make tasks like managing insurance or scheduling feel overwhelming [7]. The goal isn’t necessarily full independence by age 18, but rather a system of shared management. You can slowly build their confidence by scaffolding tasks, an approach that helps increase patient activation—the knowledge, skills, and confidence a person has in managing their own health [8].

  • Practical Steps: Start small by having your teenager check in at the front desk, fill out their own medical history forms, or be the first to speak and answer the doctor’s questions during appointments.

When a teenager turns 18, they legally become an adult. This means doctors can no longer discuss their care with a parent without explicit permission. If your young adult will still need help managing their healthcare, it is important to plan for this legal shift. Options to discuss with your care team or legal counsel include signing HIPAA release forms (which allow doctors to share medical information with you), establishing a Healthcare Power of Attorney, or creating a Supported Decision-Making agreement.

Identifying Adult Specialists Early

Pediatric NF clinics often provide a comprehensive “one-stop shop” for care, but adult medical systems are usually more fragmented. Long-term management of NF1 in adults still requires a multidisciplinary approach to monitor for potential complications [9][10].

Ideally, care should be coordinated through a specialized adult NF1 clinic [9][11]. If an adult NF clinic is not available locally, you will need to help your teenager build a team that typically includes:

  • A primary care physician (internist or family medicine doctor) who is willing to learn about NF1.
  • An adult neurologist or clinical geneticist familiar with the condition.
  • A genetic counselor, as young adults may begin considering family planning and inheriting risks.
  • A mental health professional, as managing a chronic condition into adulthood can be stressful.
  • Other specialists based on specific needs, such as an oncologist, dermatologist, or endocrinologist [10][12].

Medical History and Tumor Baselines

One of the most critical steps in the transition is ensuring the new adult care team understands your teenager’s baseline health. A comprehensive “Transition Packet” or medical summary must be created by the pediatric team and given to the adult providers.

This summary should include:

  • The specific genetic mutation, if known.
  • A complete surgical and treatment history.
  • Tumor Baselines: A clear record of the size, location, and status of existing tumors, particularly plexiform neurofibromas (large, complex nerve tumors).

Knowing the baseline of these tumors is vital. Patients with NF1 must undergo prompt medical evaluation if a plexiform neurofibroma changes in size, causes new pain, or changes in consistency, as this can be a sign of malignant transformation into a Malignant Peripheral Nerve Sheath Tumor (MPNST), an aggressive form of cancer [13][14]. Without accurate baseline imaging and records, an adult provider will not know if a tumor has recently changed.

Fostering Self-Advocacy

Ultimately, the goal is for the teenager to become their own best advocate. They should be able to clearly communicate their medical history and know exactly what symptoms require immediate medical attention—such as new or worsening pain, weakness, or rapid tumor growth [13][6].

Because adult doctors can sometimes be intimidating or rushed, it helps to practice specific phrases. Teach your teenager to say:

  • “I have a complex condition called NF1, and I have a few questions written down.”
  • “Can you please explain that in a different way?”
  • “I know my body, and this pain feels different than my baseline.”

Common questions in this guide

When should we start planning the transition from pediatric to adult NF1 care?
Transition planning should ideally begin early in adolescence, typically between the ages of 12 and 14. Starting this early gives teenagers several years to practice managing their health and navigating the healthcare system while still under the guidance of a parent or guardian.
What types of adult specialists do I need for NF1?
Adult NF1 care is best coordinated through a specialized adult NF clinic. If one is not available, you should build a team that includes a primary care physician, an adult neurologist or clinical geneticist, a genetic counselor, and potentially mental health professionals or oncologists.
What medical records do I need to give to my new adult NF1 doctor?
Your new adult providers need a comprehensive summary of your medical history from your pediatric team. This must include your specific genetic mutation, surgical history, and a clear baseline record of the size, location, and status of any existing tumors, especially plexiform neurofibromas.
How does turning 18 change my medical privacy and parental involvement?
When you turn 18, doctors can no longer discuss your care with a parent without your explicit permission. If you still want your parents involved in your healthcare, you will need to sign HIPAA release forms or establish a Healthcare Power of Attorney.
What tumor symptoms should I report to my doctor immediately?
You should immediately seek medical evaluation if you notice a plexiform neurofibroma changing in size, causing new pain, or changing in consistency. These can be warning signs that the tumor is transforming into an aggressive cancer called a Malignant Peripheral Nerve Sheath Tumor (MPNST).

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What age does your pediatric clinic typically formalize the transfer to adult care, and how do we begin the process?
  2. 2.Can you provide a comprehensive summary of my medical history, including specific tumor baselines and imaging records, to share with my future adult providers?
  3. 3.Which specific adult specialists (such as neurology, genetics, or oncology) do you recommend we establish care with first?
  4. 4.Is there an adult NF1 specialty clinic in our area that you refer patients to?
  5. 5.(For a new adult primary care doctor) I have a complex genetic condition; are you comfortable consulting with NF1 specialists if my care requires it?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Incorporating the Six Core Elements of Health Care Transition Into a Medicaid Managed Care Plan: Lessons Learned From a Pilot Project.

    McManus M, White P, Pirtle R, et al.

    Journal of pediatric nursing 2015; (30(5)):700-13.

    PMID: 26239121
  2. 2

    Optimizing the Transition and Transfer of Care in Pediatric Inflammatory Bowel Disease.

    Fishman LN, Ding J

    Gastroenterology clinics of North America 2023; (52(3)):629-644 doi:10.1016/j.gtc.2023.05.004.

    PMID: 37543405
  3. 3

    Neurofibromatosis Type 1 (NF1): Addressing the Transition from Pediatric to Adult Care.

    Radtke HB, Berger A, Skelton T, Goetsch Weisman A

    Pediatric health, medicine and therapeutics 2023; (14()):19-32 doi:10.2147/PHMT.S362679.

    PMID: 36798587
  4. 4

    Health Care Transition for Adolescents and Young Adults With Pediatric-Onset Liver Disease and Transplantation: A Position Paper by the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition.

    Vittorio J, Kosmach-Park B, King LY, et al.

    Journal of pediatric gastroenterology and nutrition 2023; (76(1)):84-101 doi:10.1097/MPG.0000000000003560.

    PMID: 35830731
  5. 5

    Transition Readiness Assessment in Adolescents and Young Adults with Neurofibromatosis Type 1 (NF1).

    Goetsch Weisman A, Haws T, Lee J, et al.

    Comprehensive child and adolescent nursing 2023; (46(3)):223-239 doi:10.1080/24694193.2020.1806402.

    PMID: 32969737
  6. 6

    Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study.

    Siegel A, Lockridge R, Struemph KL, et al.

    Journal of pediatric psychology 2024; (49(6)):383-391 doi:10.1093/jpepsy/jsae006.

    PMID: 38366576
  7. 7

    Written language achievement in children and adolescents with neurofibromatosis type 1 and Plexiform Neurofibromas.

    Siegel A, Toledo-Tamula MA, Martin S, et al.

    Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence 2024; (30(7)):1095-1115 doi:10.1080/09297049.2024.2307663.

    PMID: 38318699
  8. 8

    Uptake of health monitoring and disease self-management in Australian adults with neurofibromatosis type 1: strategies to improve care.

    Crawford HA, Barton B, Wilson MJ, et al.

    Clinical genetics 2016; (89(3)):385-91 doi:10.1111/cge.12627.

    PMID: 26081173
  9. 9

    Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

    Stewart DR, Korf BR, Nathanson KL, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2018; (20(7)):671-682 doi:10.1038/gim.2018.28.

    PMID: 30006586
  10. 10

    Uncommon Thigh Mass in Neurofibromatosis Type 1: Unveiling Aggressive Epithelioid Sarcoma.

    Gharbi MA, Limaiem F, Romdhane KB, et al.

    European journal of case reports in internal medicine 2024; (11(4)):004432 doi:10.12890/2024_004432.

    PMID: 38584901
  11. 11

    Plexiform Neurofibroma: A Case Report.

    Bang K, Shenoi R, Waghchoure AV

    Cureus 2024; (16(7)):e65747 doi:10.7759/cureus.65747.

    PMID: 39211690
  12. 12

    Detection of severe hypertension in a patient with neurofibromatosis type 1 during anesthesia induction: a case report.

    Wang J, Wei G, Wang Z, Huang H

    Journal of medical case reports 2019; (13(1)):349 doi:10.1186/s13256-019-2292-4.

    PMID: 31783902
  13. 13

    Enlarging Plexiform Tumor in a Pregnant Patient with Neurofibromatosis Type One.

    Williams S

    Cureus 2018; (10(6)):e2802 doi:10.7759/cureus.2802.

    PMID: 30116681
  14. 14

    ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1.

    Carton C, Evans DG, Blanco I, et al.

    EClinicalMedicine 2023; (56()):101818 doi:10.1016/j.eclinm.2022.101818.

    PMID: 36684394

This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider about transitioning care and your specific medical situation.

Get notified when new evidence is published on Neurofibromatosis type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.